Eupraxia Pharmaceuticals Inc. EPRX
7.88 USD -0.19 (-2.30%)
Nov 12, 2026, 2:43 PM EST
7.62 Day range 8.06
5.63 52-week range 9.32
- YTD
- +4.30%
- 1 year
- +19.32%
Benzinga news
benzinga.com HC Wainwright & Co. Maintains Buy on Eupraxia Pharmaceuticals, Raises Price Target to $16 HC Wainwright & Co. analyst Brandon Folkes maintains Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and raises the price target from $11 to $16.
benzinga.com Eupraxia Announces $125M At-The-Market Equity Program; Says No Current Plan To Use ATM Program In Near Term Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize…
benzinga.com Eupraxia Pharmaceuticals Q3 EPS $(0.23) Beats $(0.28) Estimate Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.28) by 17.86 percent. This is a 21.05 percent decrease over…- benzinga.com RBC Capital Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $14 RBC Capital analyst Douglas Miehm initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Outperform rating and announces Price Target of $14.
benzinga.com Eupraxia Reaches Its Target Enrollment Of 120 Patients In Phase 2b Placebo-Controlled Blinded Portion Of RESOLVE Trial Eupraxia reached its target enrollment of 120 patients in the Phase 2b placebo-controlled blinded portion of the RESOLVE trial The Company has a statistical team who are doing periodic reviews of the…
benzinga.com HC Wainwright & Co. Reiterates Buy on Eupraxia Pharmaceuticals, Maintains $11 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and maintains $11 price target.
benzinga.com Wedbush Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $17 Wedbush analyst Martin Fan initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Outperform rating and announces Price Target of $17.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Gelteq (NASDAQ:GELS) stock moved upwards by 20.3% to $0.84 during Wednesday's after-market session. The company's market cap stands at $5.6 million. Nyxoah (NASDAQ:NYXH) shares increased by…
benzinga.com Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other stocks rallied on strong results.
benzinga.com Eupraxia Pharmaceuticals Q2 EPS $(0.23), Inline Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which met the analyst consensus estimate. This is a 11.54 percent increase over losses of $(0.26) per share from…
benzinga.com Oppenheimer Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $17 Oppenheimer analyst Jay Olson initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Outperform rating and announces Price Target of $17.
benzinga.com VNET Group, Akari Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session US stock futures up, VNET Group shares down 3.8% after reporting Q1 loss of $(1.20) per share on $390.133 million sales. Other stocks also fall.
benzinga.com Why JOYY Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket Gainers: PHGE +97.3%, ARTL +74.8%, QTEX +52.4%, MNTX +34.4%, HLIT +28.3%, WOK +25%, CPSH +24.7%, CODX +22.7%, MDAI +22%. Losers: AKTX -25.2%, RYOJ -18.6%, DEVS -18.6%, AKAN -17%, ADTX -16.3%, LFS…
benzinga.com This SailPoint Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday Top analysts changed outlook on top names. See all rating changes at benzinga.com/analyst-stock-ratings. Considering SAIL stock? Here's what analysts say.- benzinga.com Stifel Initiates Coverage On Eupraxia Pharmaceuticals with Buy Rating, Announces Price Target of $25 Stifel analyst Annabel Samimy initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy rating and announces Price Target of $25.
- benzinga.com Eupraxia Pharmaceuticals Q1 EPS $(0.23) Misses $(0.22) Estimate Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by 4.55 percent. This is a 9.52 percent decrease over…
benzinga.com Eupraxia Reports Early Trial Results For EoE Drug, Doses Show Response In Mid-Stage Study Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize…- benzinga.com HC Wainwright & Co. Reiterates Buy on Eupraxia Pharmaceuticals, Maintains $11 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and maintains $11 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Eupraxia Pharmaceuticals, Maintains $11 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and maintains $11 price target.
- benzinga.com Eupraxia Pharma Announces 36-Week Tissue Health And Symptom Data From Patients In Highest Dose Cohort From Ongoing Phase 1b/2a Part Of RESOLVE Trial Evaluating EP-104GI For Treatment Of EoE This is the first release of 36-week symptom response & tissue health data for the highest dose (Cohort 9) from the dose escalation portion of Eupraxia's RESOLVE trial. At 36 weeks, patients in…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session 
benzinga.com Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst William Blair starts Eupraxia at Outperform as the analyst flags unmet need and sizable market potential.
benzinga.com Semtech To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday Wall Street analysts changed outlook on top names: Morgan Stanley raised Lemonade's PT to $85, Mizuho cut Canadian Solar's PT to $19, Piper Sandler raised Tandem Diabetes' PT to $33, Stifel increased…- benzinga.com Eupraxia Reports Up To 76% Remission In Study, Advances Next Phase Of Treatment Development Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize…
- benzinga.com HC Wainwright & Co. Maintains Buy on Eupraxia Pharmaceuticals, Lowers Price Target to $11 HC Wainwright & Co. analyst Brandon Folkes maintains Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and lowers the price target from $12 to $11.
benzinga.com Eupraxia Pharmaceuticals Q4 EPS $(0.37) Misses $(0.16) Estimate Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.16) by 131.25 percent. This is a 68.18 percent decrease over…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com Eupraxia Pharmaceuticals Commences Common Stock Offering; Terms Not Disclosed Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Cantor Fitzgerald Maintains Overweight on Eupraxia Pharmaceuticals, Raises Price Target to $19 Cantor Fitzgerald analyst Kristen Kluska maintains Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Overweight and raises the price target from $11 to $19.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Eupraxia Pharmaceuticals, Maintains $12 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and maintains $12 price target.
benzinga.com Eupraxia Trial Data Shows Lasting Tissue Healing In Patients With Inflamed Esophagus Eupraxia Pharmaceuticals reported new trial data showing EP-104GI improved esophagus tissue health and maintained remission in EoE patients, with no serious safety issues reported.- benzinga.com Eupraxia Pharma Reports 12-Week And 36-Week Tissue Health Data From Ongoing Phase 1b/2a Part Of RESOLVE Trial Evaluating EP-104GI For Treatment Of Eosinophilic Esophagitis At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete improvement in tissue health. At lower doses, patients maintained the…
- benzinga.com Eupraxia Pharma Announces Second Set Of 52-Week Follow Up Data From Ongoing Phase 1b/2a RESOLVE Trial Evaluating Single Administration EP-104GI For EoE Treatment The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability data previously reported from Cohort 5; Cohorts 5 & 6 are the only groups to reach 52 weeks thus…
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market session. The company's market cap stands at $2.2 million.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com Why Venus Concept Shares Are Trading Higher By Over 32%; Here Are 20 Stocks Moving Premarket - benzinga.com Why Urban Outfitters Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
- benzinga.com Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket Shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares rose sharply during today’s pre-market trading after the company presented new data from CLEAR outcomes at ACC.24 highlighting value of…